Please use this identifier to cite or link to this item:
Title: Current Therapeutics and Future Perspectives to Ocular Melanocytic Neoplasms in Dogs and Cats
Authors: Guimarães, Tarcísio Guerra 
Cardoso, Karla Menezes 
Tralhão, Pedro 
Marto, Carlos Miguel 
Alexandre, Nuno
Botelho, Maria Filomena 
Laranjo, Mafalda 
Keywords: melanocytic neoplasms; melanoma; therapeutics
Issue Date: 20-Dec-2021
Project: PhD fellowship (SFRH/BD/139319/2018). 
POCI-01- 0145-FEDER-007440 
Serial title, monograph or event: Bioengineering
Volume: 8
Issue: 12
Abstract: Neoplasms of melanocytic origin are diseases relevant to dogs and cats' ophthalmic oncology due to their incidence, potential visual loss, and consequent decrease in life quality and expectancy. Despite its non-specific clinical presentation, melanocytic neoplasms can be histologically distinguished in melanocytomas, which present benign characteristics, and malignant melanomas. The diagnosis often occurs in advanced cases, limiting the therapeutic options. Surgery, cryotherapy, radiotherapy, photodynamic therapy (PDT), and laser are currently available therapeutic strategies. As no clinical guidelines are available, the treatment choice is primarily based on the clinician's preference, proficiency, and the owner's financial constraints. While surgery is curative in benign lesions, ocular melanomas present a variable response to treatments, besides the potential of tumour recurrences or metastatic disease. This review presents the currently available therapies for ocular melanocytic neoplasms in dogs and cats, describing the therapeutic, indications, and limitations. Additionally, new therapeutics being developed are presented and discussed, as they can improve the current treatment options.
ISSN: 2306-5354
DOI: 10.3390/bioengineering8120225
Rights: openAccess
Appears in Collections:FMUC Medicina - Artigos em Revistas Internacionais
I&D ICBR - Artigos em Revistas Internacionais
I&D CIBB - Artigos em Revistas Internacionais

Show full item record

Google ScholarTM




This item is licensed under a Creative Commons License Creative Commons